At a glance
- Originator Laboratoires Pharmascience
- Class Antidementias; Neuroprotectants
- Mechanism of Action Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 01 Feb 2001 Discontinued-preclinical in Alzheimer's disease in France (Unknown route)
- 25 Aug 1998 No-Development-Reported for Alzheimer's disease in France (Unknown route)
- 22 Apr 1996 New profile